Sevion Therapeutics (OTCMKTS:SVON) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Sevion Therapeutics (SVON) traded down $0.01 during mid-day trading on Friday, hitting $0.39. 49,800 shares of the stock were exchanged, compared to its average volume of 343,818. Sevion Therapeutics has a 52 week low of $0.13 and a 52 week high of $0.44.

COPYRIGHT VIOLATION NOTICE: “ValuEngine Downgrades Sevion Therapeutics (SVON) to Sell” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/02/valuengine-downgrades-sevion-therapeutics-svon-to-sell.html.

Sevion Therapeutics Company Profile

Sevion Therapeutics, Inc is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies.

Receive News & Stock Ratings for Sevion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sevion Therapeutics Inc and related stocks with our FREE daily email newsletter.